因素XIII:在血液静止,血栓形成和疾病中的驱动 (交叉) 联系
James P Luyendyk1, Matthew J Flick2, Alisa S Wolberg3
1Michigan State University, East Lansing, Michigan, United States.
Blood
|January 27, 2025
概括
因子XIII (FXIII) 通过交叉连接纤维素来稳定血栓,这对血液静止和伤口愈合至关重要. 它独特的机制影响血栓形成和炎症性疾病.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 血栓对于静血至关重要,因为它们依赖纤维素网络来保持结构完整.
- 第十三因子 (FXIII) 是一种对稳定这种纤维素网络至关重要的前转质氨酶.
- 激活的FXIII (FXIIIa) 产生共价交叉链,增强凝块的稳定性并影响疾病过程.
研究的目的:
- 审查XIII因子的生物学和功能.
- 探索FXIII的生物化学和生物物理影响.
- 讨论FXIII对血液静止,血栓形成和疾病的影响.
主要方法:
- 关于XIII因子在凝血中的作用的文献综述.
- 分析FXIII的生物化学和生物物理性质.
- 综合了关于FXIII生理和病理相关性的数据.
主要成果:
- FXIIIa引入了不可逆转的交叉链接,显著影响了凝块的组成和机械特性.
- FXIII在血液静止,伤口愈合和血栓形成中发挥着中心作用.
- FXIII的失调与与凝血相关的各种促炎性疾病有关.
结论:
- 第十三因子对于纤维素凝块的稳定性和完整性至关重要.
- 了解FXIII的独特机制是解决其在健康和疾病中的作用的关键.
- 对FXIII的生物物理影响和 (病理) 生理学作用的进一步研究是有必要的.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
602
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
602
01:20Extrinsic and Intrinsic Pathways of Hemostasis
5.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.0K
01:16Clot Retraction and Fibrinolysis
3.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.6K
01:09Coagulation
4.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
4.4K
01:24Disorders of Hemostasis
690
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
690
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K